Synergy between interleukin -12 ( IL -12 ) and B7 -1 ( CD80 ) for cancer immunotherapy has previously been demonstrated in animal models of breast cancer, lymphoma, and multiple myeloma. With a view to human clinical application, tricistronic retroviral and adenovirus vectors co -expressing IL -12 ( IL -12p40 plus IL -12p35 ) and CD80 were constructed by utilizing two internal ribosome entry site ( IRES ) sequences to link the three cDNAs. A murine stem cell virus ( MSCV ) -based retroviral vector ( MSCV -hIL12.B7 ) utilized distinct IRES sequences from the encephalomyocarditis virus ( EMCV ) and the foot -and -mouth disease virus ( FMCV ), whereas Ad5 -based adenovirus vectors contained transcriptional units with two EMCV IRES sequences under the control of murine ( AdMh12.B7 ) or human ( AdHh12.B7 ) cytomegalovirus promoters. AdMh12.B7 was found to consistently direct higher levels of IL -12 and CD80 expression than AdHh12.B7 following infection of a number of human tumor cell lines. In preclinical studies, the human myeloma cell line U266 was infected with MSCV -hIL12.B7 and a resulting clonal cell line, U / MSCV -h12.B7, was generated with stable expression of CD80 and secreting IL -12 at 1 ng / 24 h / 10 6 cells. By comparison, following AdMh12.B7 infection, 81% of infected U266 cells ( U / AdMh12.B7 ) expressed CD80 and secreted IL -12 at 25 ± 50 ng / 24 h / 10 6 cells. Both engineered myeloma cell lines stimulated enhanced allogeneic mixed lymphocyte proliferation and provoked increases in cytotoxic T -lymphocyte responses and -interferon release from normal donor lymphocytes exposed to parental U266 cells. These results suggest potential clinical utility of AdMh12.B7 in immunotherapy strategies for the treatment of multiple myeloma and other cancers.
D espite the expression of unique tumor-associated antigens, malignant cells grow progressively in immunocompetent hosts. Alteration of the local tumor cytokine concentration has been demonstrated to overcome this failure of immune recognition in murine models. 1 ± 3 In such models, intratumoral expression of cytokines has been achieved using viral vectors for gene delivery. The ectopic expression of cytokines by tumor cells has thus been demonstrated to eradicate established tumors and to confer protective immunity against tumor challenge. 4 The biologic activity of such an approach has been confirmed in subsequent human Phase I trials. 5 ± 7 Such immune -mediated tumor rejection appears to depend mainly upon a cytotoxic T-lymphocyte (CTL ) response, requiring a primary antigen-specific signal delivered through the T-cell receptor ( TCR ) via the antigen± MHC complex. 8 B7 -1 (CD80 ) is a member of the B7 family of co -stimulatory molecules expressed on antigen-presenting cells, and its interaction with CD28 on the T cell is required at the time of TCR engagement to mediate T-cell activation. 9 Because tumor cells generally lack CD80 and other co-stimulatory molecules, the antigen± MHC /TCR interaction of tumor and T cell, rather than lead to recognition of tumor-associated antigen, instead leads to anergy. 10, 11 Consistent with this scenario, the introduction of CD80 into tumor cells can lead to tumor rejection and confers a protective, immune -based, antitumor response against subsequent challenge with unmodified parental cells. 12, 13 IL -12 is a heterodimeric cytokine consisting of two distinct genes encoding disulfide-linked 40-and 35 -kDa subunits, and their co-expression in the same cell is required for the production of biologically active protein. 14, 15 Produced by activated monocyte ±macrophages, dendritic cells, and stimulated B lymphocytes, IL -12 has been shown to stimulate a T H 1 -mediated cellular immune response, promote the proliferation and maturation of CTLs and natural killer (NK ) cells, and enhance the cytolytic capacity of these cells at least in part via the production of -interferon ( IFN -). 16, 17 Whereas IL -12 used alone has significant antitumor activity, the co -expression of CD80 with IL-12 following gene transfer is more efficient in mediating complete regression of established malignancy and protection against rechallenge. 18 ± 21 One of the clinical targets under consideration for immunotherapy is multiple myeloma, a terminally differentiated B-cell malignancy of plasma. Autologous stem cell transplantation can mediate frequent complete remissions, but 76% of transplanted myeloma patients relapses within 5 years of the time of transplant. 22 Eradicating minimal residual disease following stem cell transplant has therefore become a therapeutic priority in myeloma. Immunotherapy may play a role in eradicating minimal residual myeloma because patients relapsing after an allogeneic bone marrow transplant can be successfully treated with allogeneic T cells that mediate a graft -versus -myeloma effect. 23, 24 It also appears that myeloma cells do express tumor-associated antigens recognizable by both autologous or allogeneic T cells. 25, 26 These findings together suggest that the basic tenets of immunotherapy hold true for myeloma, i.e., that myeloma cells express tumor-associated antigen( s ) and can be targeted and eliminated by primed T cells.
In anticipation of using IL -12 and CD80 for the immunotherapy of multiple myeloma and other cancers in clinical trials, we report here the introduction of tricistronic expression cassettes in retroviral and adenovirus vectors for co -expression of both subunits of IL-12 in conjunction with CD80. We studied the biologic function of these vectors by in vitro immunologic assays using human myeloma cell lines. Specifically, allogeneic donor lymphocyte proliferation and CTL response induced by retrovirally and adenovirally infected myeloma cells expressing IL -12 /CD80 were assessed.
MATERIALS AND METHODS

Construction of retroviral vectors
The cDNA of human IL -12 p40 and p35 and of the costimulatory molecule CD80 were a gift of Genetics Institute (Andover, MA ). The 2.3 -kb IL -12p40 cDNA was inserted at the XbaI site and the 1.3 -kb IL -12p35 cDNA was inserted at PstI site of the pED( EMC ) vector. The human B7 -1 cDNA was inserted in the pCDM8 vector ( Invitrogen, Carlsbad, CA ) at the BstXI site. Co -expression of the IL -12 and CD80 was accomplished by utilizing internal ribosome entry site ( IRES ) sequences from the 5 H untranslated regions of picornaviruses, which confer a cap -independent initiation of translation at internal AUGs. 27 To prevent problems of instability experienced with a previously constructed IL -12 retroviral vector in which two identical flanking encephalomyocarditis virus ( EMCV ) IRES sequences were employed, 28 we used two different IRES sequences that exhibit only 50% similarity. The IRES sequences were from the foot -andmouth disease virus ( FMDV ) (provided by Dr. Esteban Domingo, Universidad Autonoma, Madrid, Spain ) 27 and from the EMCV ( a gift of J. Majors Washington School of Medicine, St. Louis, MO ), the latter of which we had previously successfully utilized to express murine IL-12.
28,29 The MSCV-hIL12.B7 vector was constructed in several steps by replacing the sequences between the XhoI and BamHI sites of the MSCV-based MINV retroviral vector 30 with a tricistronic IL -12 and CD80 expression cassette, hIL-12p40 -IRES FMDV -hIL -12p35 -IRES EMCV -CD80 (Fig 1) . Stable PG13 producer cell lines 31 were generated exporting functional recombinant MSCV-hIL12.B7 retroviral particles carrying the GaLV envelope.
Construction of adenovirus vectors
An E1 -, E3-deleted adenovirus vector was constructed using the hIL -12p40 -IRES FMDV -hIL -12p35 -IRES EMCV -hB7 -1 cassette and rescued according to previously published procedures. 32 Although CD80 was expressed on infected cells, IL -12 production was unusually low (ng /mL amounts ) from this vector. The IL -12.CD80 expression cassette was therefore modified to contain two identical EMCV IRES sequences under the control of either the murine or human Figure 1 . Construction of tricistronic retroviral and adenoviral vectors. A: MSCVhIL12.B7 retrovirus. A schematic representation of the MSCVhIL12.B7 retrovirus displays the hIL12p40 and hIL -12p35 subunits linked by the IRES1 sequence that represents IRES from a FMDV mutant ( IRES FMDV ). IRES2 denotes the sequence from the EMCV ( IRES EMCV ) linking the hIL -12p35 subunit to hB7 -1. The construct is flanked by long terminal repeat sequences ( LTRs ) and the enzymatic splice site is displayed. B: IL -12.CD80 adenoviral constructs. The final AdHh12.B7 construct includes a cassette of HCMV promoter hp40 -IRES EMCV -hp35 -IRES EMCV -CD80 -SV40 poly A in the E1 region of Ad5. The final AdMh12.B7 construct was identical to the above cassette except the replacement of human CMV promoter with mouse CMV promoter. Both IRES sequences in these two adenoviral constructs were derived from the EMCV. ITR denotes inverted terminal repeat of adenovirus vector.
Cancer Gene Therapy, Vol 8, No 5, 2001 cytomegalovirus (CMV ) promoter. In the re -configured cassette, the EMCV IRES was obtained from the pCITE2 plasmid (Novagen, Madison, WI ) and the hB7 -1 cDNA utilized was obtained from the plasmid pCA13qhB7 ( a gift of Dr. S. Dessureault, Mt. Sinai Hospital, Toronto, Canada ). 33 The resulting IL-12.CD80 expression cassette was ligated into the adenovirus shuttle plasmid pMH4 to create pMH12B7, and following co -transfection with pBHG10, 34 individual plaques were isolated and used to infect 293 cells. The final AdMh12.B7 construct contained the following cassette: murine CMV promoter-hIL -12p40 -IRES EMCVhIL -12p35-IRES EMCV -CD80 -1 -SV40polyA, in the E1 region of Ad5. AdHh12.B7 was identical except that the human CMV promoter was used instead of the murine CMV promoter.
Cell lines and culture
The U266 human myeloma cell line was grown in Iscove's modified Dulbecco's medium with 10% fetal bovine serum ( FBS ). ANBL -6 cells ( gift of Dr. Diane Jelinek ) were grown in Iscove's modified Dulbecco's medium with 10% FBS plus 2% IL -6 conditioned media. The human myeloma cell lines, OCIMy5 (My5 ), were cultured in RPMI media with 10% FBS. Cultures were maintained in a humidified atmosphere containing 5% CO 2 at 378C.
Retroviral infection of human cell lines
The U266 (human myeloma ) and Namalwa ( human lymphoma ) cell lines were incubated for 8 ±12 hours at 378C, 5% CO 2 with 5 mL of supernatant from the PG13 producer cell line, containing MSCV-hIL12.B7 retroviral vector particles, in the presence of 2 g /mL polybrene with up to four rounds of infection alternating with selection for CD80 expression by FACS analysis. The latter was incubated for 2 hours in 1 mL of supernatant from the PG13 producer cell line at 378C, 5% CO 2 with 8 g /mL polybrene, at which time 3 mL of media was added and cultured for a further 24 hours. Cells were then expanded and clones isolated based on surface expression of CD80 as described below.
Adenovirus infection of human cell lines
Cell lines, including U266, My5, ANBL -6, K562, and Namalwa cells, were infected with Addl70.3 (Addl, an E1 -deleted virus lacking a transgene insert ) 35 or with AdMh12.B7 or AdHh12.B7 at multiplicity of infection ( MOI ) of 100 at 378C, 5% CO 2 for 1 hour. Cells were washed three times with medium and returned to culture. Media were changed daily and tested for human IL -12 expression by enzyme -linked immunosorbent assay ( ELISA ). Cells were harvested as required for CD80 analysis for use as targets in CTL assays, or for T-cell priming in lymphocyte proliferation assays as described below. As further controls, cell lines were also infected with adenovirus vectors AdB7 or AdIL12 ( unpublished ), respectively. AdB7 expresses CD80 alone under control of the human CMV promoter 33 (gift of Dr. Sophie Dessureault ).
Functional assay of adenovirus -derived human IL-12, production and quantification of INF -IL -12 heterodimer quantification in virus -infected cell -free supernatants was performed by ELISA ( R&D Systems, Minnesotta, MN ). In functional bioassays, normal human peripheral blood mononuclear cells ( PBMCs) were prestimulated with 5 g /mL PHA for 5 days. Cells were then washed once and seeded in 96 -well plates ( 5Â10 4 cells / well). Conditioned media from AdIL12 -or AdMh12.B7-transduced U266 cells or recombinant human IL -12 were added to the cell culture in triplicates. Cell proliferation assay was measured by MTT assay (Boehringer Mannheim, Laval, Quebec, Canada ) on day 8.
For INF -induction and quantification, U266 and My5 cells were first infected by Addl, AdIL -12, AdB7, or AdMh12.B7 at MOI of 100:1 for 1 hour, respectively. Twenty -four hours after infection, the cells were irradiated with 25 Gy and washed with AIM -V serum -free media. For 6 days, 1Â10
5 irradiated cells were co -cultured with 2Â10 6 enriched human T cells in a six -well plate in 2 mL of AIM -V media. The supernatants were measured for INFproduction using O PT EIA 2 Human INF -ELISA kit ( PharMingen, Mississauga, Ontario, Canada ).
Flow cytometric analysis of CD80 and cell sorting
Expression of CD80 was examined by immunofluorescence flow cytometric analysis using a phycoerythrin -conjugated mouse antihuman CD80 monoclonal antibody ( Becton Dickinson, Mississauga, Ontario, Canada ). Briefly, cells were washed twice and resuspended in fresh media then stained at 48C for 30 minutes. Viable cells were gated by a combination of forward and orthogonal light scatter and analyzed on a FACScan flow cytometer using CellQuest 
T -cell enrichment and proliferation assay
Human T cells were isolated from fresh peripheral blood of healthy donors by Ficoll-Hypaque density gradient centrifugation, followed by treatment with Lympho -Kwik TLymphocyte Isolation Reagent (One Lambda, Carlsbad, CA ). Cells obtained were 77± 85% CD3
+ by FACS analysis. T cells( 1Â10 6 ) isolated in this manner were cultured in 1 mL of serum -free AIM -V medium plus 10 g/mL phytohemagglutinin ( Gibco BRL, Burlington, Ontario, Canada ) at 378C, 5% CO 2 for 4 days.
Lymphocyte proliferation assays were performed as previously described. 36 T cells ( 5Â10 4 ) isolated as described above were co -cultured with retrovirally or adenovirally infected -irradiated ( 25 Gy ) tumor cells ( 1Â10 4 ) in serumfree AIM -V medium in triplicate in 96-well flat -bottom microtiter plates and cultured at 378C, 5% CO 2 for 6 days. During the last 8 hours of the 6-day culture, cells were pulsed with 0.5 Ci 3 cells were co -incubated with effector cells in triplicate at various effector:target ( E:T ) ratios in a total volume of 200 L of RPMI 1640 plus 10% FBS in 96 -well round -bottom plates for 4 hours at 378C. Aliquots of 100 L of supernatant were then removed for cpm quantification by liquid scintillation counting. Maximum release was determined by treating target cells with 1% Triton X -100, and spontaneous release was determined by incubating target cells with medium only. Cytotoxity was expressed as percent specific lysis ( PSL ) that was calculated as ( experimental release À spontaneous release)Â100 /(maximum release À spontaneous release ).
RESULTS
Concomitant expression of IL -12 and CD80 from a tricistronic retroviral vector
The MSCV-based MSCV-hIL12.B7 retroviral vector contains a tricistronic expression cassette as diagramed in Figure  1A . Two distinct IRES sequences, from FMDV and EMCV, were utilized because homologous recombination between tandem identical EMCV IRES sequences had been observed in a previous retroviral vector system. 28 This vector was electroporated into the GP +E -86 ecotropic cell line, and transiently produced viral particles were utilized to infect the PG13 producer cell line to generate retrovirus particles carrying the GaLV envelope. further preclinical studies, a clonal U266 cell line designated U /MSCV-h12.B7 was generated by single cell sorting based on CD80 expression. U /MSCV-h12.B7 cells produce IL-12 at a concentration of 1 ng IL -12 /10 6 cells / 24 h.
Tricistronic adenovirus vectors with two EMCV IRES sequences are functional
For unknown reasons, the tricistronic expression cassette hIL -12p40 -IRES FMDV -hIL -12p35 -IRES EMCV -hB7 -1 uti- the IL -12.CD80 cassette was reengineered to contain two copies of the EMCV IRES controlling the expression of p35 and B7 -1 ( see Materials and Methods ). With these expression cassettes, two adenoviruses were rescued: AdMh12.B7 utilizing the murine CMV promoter for p40 expression and AdHh12.B7 utilizing the human CMV promoter ( Fig 1B ) .
Cells infected with the AdMh12.B7 adenovirus vector expressed higher concentrations of IL -12 and increased levels of cell surface CD80 as compared to those infected with the AdHh12.B7 vector. U266 myeloma cells infected with AdMh12.B7 expressed the highest secreted IL -12 at 55 ng /10 6 cells /24 h, and 95% of infected cells is CD80 + ( Table 1 ) . Maximal 24 -hour IL -12 release from infected U266 cells was on days 2± 3 postinfection and IL-12 secretion was still detectable at day 7, the final time point examined. To determine whether the adenovirus -derived human IL -12 is biologically active, conditioned media from Ad -infected myeloma U266 cells were quantitated for IL -12 expression and bioactivity. Both AdMh12.B7 -and AdIL -12 ±derived IL -12 demonstrated equivalent stimulation of human lymphocyte proliferation as compared to recombinant human IL -12 protein, demonstrating functional expression of IL -12 from the tricistronic vector (Fig 2 ) . Furthermore, studies on AdMh12.B7-infected 293 cells demonstrated that 80± 90% of secreted IL -12 was in heterodimeric form, which suggests that roughly equal amounts of p35 and p40 were secreted ( data not shown ).
To examine whether the insertion of the IL -12 cDNA and subsequent production of IL -12 adversely affected expression of the third cDNA CD80, CD80 expression from an AdB7 vector was compared to AdMh12.B7 vector. Both AdB7 and AdMh12.B7 infection mediated a 20 -fold increase in CD80 + U266 cells 24 hours after viral infection ( 80.6% and 81.1% positive, respectively, Figure 3 ). Nevertheless, although the percentages of infected cells were similar, expression levels were lower overall for the AdMh12.B7 virus. Because AdB7 uses the weaker HCMV promoter, the degree in reduction in CD80 expression resulting from its 3 H position in the AdMh12.B7 expression cassette cannot be more accurately gauged.
Lymphocyte proliferation is enhanced by IL -12 and CD80 expression on myeloma cells
In vitro lymphocyte proliferation assays were performed using lymphocytes from four allogeneic normal donors mixed with -irradiated U266 cells infected with MSCV-hIL12.B7 ( U /MSCV-h12.B7 cell line ), AdB7, AdMh12.B7, or the Addl70.3 (Addl, sham virus ) as stimulators. T-lymphocyte proliferation was significantly enhanced for all CD80 -and IL -12+ CD80 ± expressing U266 myeloma cells ( U /AdB7 and U /AdMh12.B7 ) compared to parental U266 or Addl sham -infected U266 cells (U / Addl, Fig 4 ) . Though AdB7 -derived CD80 alone promoted significant lymphocyte proliferation, the additional expression of IL -12 from tricistronic AdMh12.B7 further increased the proliferation index. Lymphocytes primed with U /AdMh12.B7 cells demonstrated higher proliferation than U /MSCV-h12.B7 (Fig 4) . Such a difference likely represents gene expression levels in these two systems; AdMh12.B7 mediated the production of IL -12 from U266 cells at 26 ng /10 6 cells / 24 h compared to U /MSCV-h12.B7 cells ( 1 ng /10 6 cells / 24 h). These data together indicate that retroviral-mediated IL -12 and CD80 expression by myeloma cells enhances allogeneic lymphocyte proliferation, and that increased IL -12 and CD80 expression by using adenovectors further enhances lymphocyte proliferation.
CTL killing of myeloma cells is enhanced by IL -12 and CD80
To investigate whether CTL activity would be enhanced by the co -expression of IL-12 and CD80, enriched T cells, prepared from the peripheral blood of four normal donors, were primed in triplicate with irradiated parental U266 or retrovirus -modified U /MSCV-h12.B7 cells. The mean percentage of specific lysis of parental U266 target (T ) cells induced by the resulting allogeneic effector (E ) T cells stimulated by U /MSCV-h12.B7 was higher than controls at E:T ratios of both 10:1 and 50:1 (Fig 5A ) . These differences are statistically significant by paired -mean two sample t tests with P values of .048 and .034, respectively.
CTL activity was also investigated in U266 or My5 myeloma cell lines infected with adenoviruses that expressed IL -12 and /or CD80. The resulting Ad -infected U266 and My5 cells were irradiated and used to prime CTL. Specific lysis against parental U266 cells reached 60 ±85% following the expression of adenoviral -derived IL -12, CD80 alone, or IL -12 + CD80 ( Fig 5B ) . Similarly, CTL activity against parental My5 cells was significantly increased (40 ± 95% PSL ) compared with control groups ( 10± 20% PSL ) following the viral -derived expression of CD80 and/ or IL -12. Engineered My5 cells expressing both IL-12 and CD80 demonstrated better induction of CTL activity than the My5 cells that expressed IL -12 or CD80 alone (Fig 5C ) .
Both adenovirus -derived IL -12 and CD80 promote production of INF -, but without synergy Both IL -12 and CD80 can induce differential T-cell activation and proliferation, and at least in part via the production of IFN -. 16, 17, 37 To investigate whether the adenovirus -modified myeloma cells expressing IL -12 and CD80 could stimulate the production of IFN -from primed T cells and to investigate the synergy of these tricistronic adenovirus -derived factors, we measured IFN -concentration in the media of allogeneic T cells primed with irradiated adenoviral gene -modified U266 or My5 cells. Expression of IL -12 and CD80 by myeloma cells induced the expression of IFN -in the culture. However, IL -12 demonstrated no synergy with CD80 in promoting the production of IFN - ( Fig 6 ) .
DISCUSSION
Intratumoral expression of CD80 has resulted in increased tumor immunogenicity in many murine models of cancer immunotherapy; however, expression of CD80 alone has not consistently led to systemic and effective antitumor immune responses, 38, 39 perhaps due to differences in immunogenicity based on variable tumor antigen and MHC expression. 40 These findings have prompted a search for molecules that could act synergistically with CD80 to stimulate potent immune effector function.
The heterodimeric cytokine, IL -12, is believed to promote antitumor immunity via the stimulation of a T H 1 immune response by increasing MHC expression, and by upregulating the cytotoxic activity of NK and CD8 + T cells. 41, 42 Antiangiogenic activity may also contribute to the tumoricidal effects of IL -12 against solid tumors.
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In a number of animal tumor vaccine models, the combination of IL -12 and CD80 has indeed resulted in increased tumoricidal activity and long -term immunity. Simultaneous IL-12 and CD80 expression via a vaccinia vector increased survival in a metastatic murine colon carcinoma model relative to the use of either CD80 or IL-12 gene alone. 44 Co -expression of IL -12 and CD80 following retroviral -mediated gene delivery was also superior to either gene alone in murine A20 lymphoma 19 or B9 /BM1 myeloma models. 20 Finally, injection of murine tumors in vivo with adenovirus vectors expressing IL-12 or CD80 separately was not as effective as intratumoral injection of a single vector co-expressing IL -12 and CD80. 21 Given the plethora of preclinical murine data, virusmediated delivery of IL -12 and CD80 in combination holds much promise for immunotherapy of cancer in humans. 28 In this regard, we constructed polycistronic vectors coexpressing these genes for potential clinical trial use. The IL -12.CD80 tricistronic cassette in the MSCV-hIL12.B7 retroviral vector described here, utilizing two different IRES sequences, directed stable expression of both IL -12 subunit cDNA plus the CD80 cDNA in infected target cells. It may be useful therefore in the generation of permanent genemodified tumor cell lines co-expressing IL-12 and CD80 for use as allogeneic cancer vaccines. However, IL-12 secretion was much higher when an adenovirus -based IL-12.CD80 tricistronic cassette containing two copies of the EMCV IRES was employed. Moreover, the AdMh12.B7 vector with the IL -12.CD80 cassette placed under the control of the murine CMV promoter consistently outperformed the AdHh12.B7 vector that utilized the human CMV promoter. 45 The level of CD80 expressed by AdMh12.B7 -infected U266 cells was comparable to that achieved by the control AdB7 vector (albeit using the human CMV promoter ), and the level of IL -12 production from AdMh12.B7 was equal to, and in some of the cell lines tested exceeded, that reported as being required at the tumor site to mediate rejection in vivo. 46 The secreted IL-12 protein from AdMh12.B7-infected cells appeared to be appropriately heterodimerized and the viral -derived IL-12 demonstrated equivalent bioactivity to commercial recombinant IL -12 protein in stimulation of human T-lymphocyte proliferation.
In preclinical studies, we next demonstrated that allogeneic lymphocyte proliferation was enhanced by MSCVhIL12.B7 ±infected U266 myeloma cells as compared to controls, whereas AdMh12.B7 -infected U266 cells secret-ing higher IL-12 levels stimulated the greatest overall response.
The CTL studies undertaken here address the potential of gene -modified myeloma cells to act as antigen -presenting cells, and their ability to directly stimulate cytotoxic activity. In this regard, a number of other groups have demonstrated that murine myeloma models can be treated using cytokine-modified tumor cells as cancer vaccines and that, in at least one model, CTL killing of genemodified tumor cells is granzyme B ±mediated. 47 In various murine myeloma models, IL -2, 48 GM -CSF, IL-12, 47 and IL -12 co-expressed with CD80 20 have also been demonstrated to be effective. Consistent with these in vivo observations, myeloma cells have been shown to function as antigen -presenting cells in vitro via the stimulation of strong allogeneic T-cell proliferation to soluble recall antigens Ð an effect that was dependent on myeloma MHC class I molecules. 49 Wendtenr et al 50 used myeloma cells transfected with CD80 and /or CD86 to directly activate CD3 + T cells in vitro. In humans, allogeneic T-cell infusions after allogeneic donor transplants result in improvement in myeloma. 51, 52 
CONCLUSION
We have reported the construction and testing of recombinant retroviral and adenoviral vectors carrying tricistronic transcripts encoding human IL -12 and CD80. We have further demonstrated that expression of IL-12 and CD80 by tumor cells following infection with a recombinant adenovirus vector can mediate significant lymphocyte proliferation, CTL responses against parental tumor cells in vitro, and production of IFN -from the stimulated human T cells. Based on these results, we have initiated clinical phase I trials with the AdMh12.B7 vector in multiple myeloma and other cancers.
